Pregnant on a GLP-1: What the Data Actually Shows (and What to Do Today)

If you have just found out you are pregnant while on semaglutide or tirzepatide, the first thing to know is that your fear is reasonable, and the published data on accidental human exposure during early pregnancy is more reassuring than the fear suggests. Stop the medication today. The conversation with your prescriber and your obstetric provider starts this week.

Here is the version of this conversation I would have if you walked into my clinic with the same question.

Step One: Stop Today

Neither semaglutide nor tirzepatide is recommended during pregnancy. Their FDA labels advise discontinuing the medication when pregnancy is recognized. Both cross the placenta in animal studies, and both have shown developmental effects in animals at exposures higher than typical human dosing. The standard recommendation from every clinical body that has reviewed the evidence is to discontinue GLP-1 therapy as soon as pregnancy is confirmed.

That is not a hedge, and it is not a controversial recommendation. Stop the medication today. If you have a dose scheduled this week, do not take it. If you are reading this on a Monday after taking a dose on Sunday, that dose is in your system and you cannot undo it. Stopping now is what matters.

What the Human Exposure Data Actually Shows

The data we have on accidental human exposure during early pregnancy comes mostly from registry studies, which collect outcomes from real patients who got pregnant while on a medication and reported it. The largest body of data is on semaglutide, where the Novo Nordisk pregnancy registry has been collecting cases for several years.

Early registry signals have not shown an increase in major malformations above the general 3 percent baseline rate of birth defects in the United States population. The dataset is not yet large enough to rule out small increases in specific malformations, but it is large enough that a doubling of overall rates would likely have been detected by now.

The tirzepatide human pregnancy exposure data is sparse because the medication is newer, and what has been reported so far has not raised a signal. The dataset is too small to draw firm conclusions on tirzepatide specifically, but the biology of GLP-1 receptor agonism is broadly similar across the class, so the semaglutide data informs the conversation.

I want to be careful here. "No signal" does not mean "proven safe." It means the registries have not detected an increase in major malformations above baseline. The clinical recommendation to stop is conservative and appropriate. The reassurance is that the available data, while not exhaustive, is genuinely encouraging for women who learn they were exposed early.

What to Do This Week

Beyond stopping the medication, three things are worth getting in motion this week.

Tell your obstetric provider. If you do not have one yet, call your primary care office or use the resources at your local hospital to get a first-trimester visit scheduled. Tell them you were on a GLP-1 medication at conception and through the early pregnancy. They will document the exposure, order the standard early-pregnancy labs and ultrasound, and walk you through the prenatal plan. Ask about enrolling in the manufacturer's pregnancy exposure registry (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide); voluntary reporting is how the reassuring exposure data in this article gets built.

Start a prenatal vitamin. Folate (400 to 800 mcg daily, or 1 mg for some indications) reduces the risk of neural tube defects and should ideally be started before conception. If you were not already taking one, start today. Any standard prenatal vitamin from a reputable brand is fine.

Plan for the nutrition shift. GLP-1 medications suppress appetite. Without that suppression, your appetite will rebound over the next few weeks. You may also need to gain weight during pregnancy depending on your starting point. Your obstetric provider will guide you on appropriate weight gain. Protein, vitamins, and steady eating habits matter more than ever. Our piece on what to eat on a GLP-1 covers a baseline nutrition framework that translates well even when the medication is no longer doing the appetite work.

A Word on Contraception

If you became pregnant on a GLP-1 while using an oral contraceptive, you are not alone. This matters most with tirzepatide: its FDA label specifically warns that it can reduce the effectiveness of oral hormonal contraceptives, because slowed gastric emptying changes how the pill is absorbed. The tirzepatide label advises switching to a non-oral contraceptive, or adding a barrier method, for four weeks after starting the medication and for four weeks after each dose increase. Semaglutide does not carry that specific labeled warning, but unintended pregnancies have been reported across GLP-1 therapy (the "Ozempic babies" the media has described), so contraception planning belongs in the intake conversation no matter which medication you are on, and any clinician restarting a GLP-1 after delivery should raise it again.

If and when you do restart after delivery, use a barrier method or a non-oral contraceptive (an IUD, an implant, an injection, or a patch) rather than relying on the pill alone, unless your obstetric provider specifically advises otherwise.

Common Questions

Will my weight come back? Some, but not necessarily all of it, and not necessarily quickly. Most patients who stop a GLP-1 see appetite return over a few weeks. Some weight regain over the following months is typical. Pregnancy itself involves planned weight gain (usually 25 to 35 pounds depending on starting BMI). The relevant goal during pregnancy is healthy weight gain, not weight loss.

Can I restart after delivery? That is a conversation with your obstetric and primary care providers. Breastfeeding is the next consideration. GLP-1 medications are not recommended during breastfeeding because the lactation safety data is limited. Patients who plan to breastfeed typically wait to restart until they have weaned or until they are ready to transition to formula.

When can I plan another pregnancy after restarting? For semaglutide, the FDA label specifically advises stopping at least two months before a planned pregnancy, because its roughly one-week half-life means the drug clears slowly. Tirzepatide has a shorter half-life of about five days, but the conservative, label-consistent approach is the same: stop GLP-1 therapy well in advance of trying to conceive and use reliable contraception during that window. Stopping at least two months ahead is the standard guidance.

Where Programs Often Fall Short

The GLP-1-only telehealth platforms tend to handle pregnancy discovery as a one-line "stop the medication" response and then disappear. That is not enough. Patients in this moment need a substantive conversation about the registry data, about what to expect over the next few weeks as the appetite returns, about prenatal care logistics if they do not have an OB lined up, and about the eventual restart question after delivery.

A GLP-1 should not be prescribed during pregnancy or breastfeeding. What ongoing access means here is having a clinician you can message about appetite rebound, prenatal nutrition questions, and the eventual conversation about restarting after weaning. The first-trimester decisions are between you and your obstetric provider. The restart decisions are months away. Both are easier with a clinician on the other end of the line.

For the broader view on what to expect when you eventually do restart, see the first three months piece and the five questions to ask before starting.

Bottom Line

Stop the medication today. The published human exposure data so far is reassuring. Get an obstetric visit scheduled this week. Start a prenatal vitamin. Plan the nutrition transition. The conversation about restarting is for after delivery and after breastfeeding decisions. Congratulations.

Important Information

Compounded medications are prepared by accredited US compounding pharmacies under a licensed prescriber and are not FDA-approved drug products in the way that brand-name medications such as Wegovy, Ozempic, Mounjaro, and Zepbound are. GLP-1 medications are not recommended during pregnancy, and the FDA labels advise discontinuing when pregnancy is recognized. If you become pregnant during therapy, stop the medication and contact your prescriber and obstetric provider immediately. Lactation safety is not established and GLP-1 medications are not recommended during breastfeeding. This article is educational and is not medical advice.

Sources

• US Food and Drug Administration labeling for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro).
• Novo Nordisk Pregnancy Registry for semaglutide. Annual reports.
• American College of Obstetricians and Gynecologists. Obesity in pregnancy. Practice Bulletin 230. 2021.
• Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. National Academies Press. 2009.
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.